CN101045925A - Mutual action of CAL and mGluR5 and its effect on mGluR5 expression - Google Patents
Mutual action of CAL and mGluR5 and its effect on mGluR5 expression Download PDFInfo
- Publication number
- CN101045925A CN101045925A CN 200710086478 CN200710086478A CN101045925A CN 101045925 A CN101045925 A CN 101045925A CN 200710086478 CN200710086478 CN 200710086478 CN 200710086478 A CN200710086478 A CN 200710086478A CN 101045925 A CN101045925 A CN 101045925A
- Authority
- CN
- China
- Prior art keywords
- cal
- mglur
- protein
- expression
- gst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 title description 4
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 title description 4
- 230000000694 effects Effects 0.000 title description 4
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract description 55
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract description 55
- 102100036675 Golgi-associated PDZ and coiled-coil motif-containing protein Human genes 0.000 abstract description 45
- 101001028052 Homo sapiens Filamin-binding LIM protein 1 Proteins 0.000 abstract description 45
- 101001072499 Homo sapiens Golgi-associated PDZ and coiled-coil motif-containing protein Proteins 0.000 abstract description 45
- 108090000623 proteins and genes Proteins 0.000 abstract description 45
- 102000004169 proteins and genes Human genes 0.000 abstract description 40
- 230000003993 interaction Effects 0.000 abstract description 6
- 230000001413 cellular effect Effects 0.000 abstract description 5
- 238000013518 transcription Methods 0.000 abstract description 4
- 230000035897 transcription Effects 0.000 abstract description 4
- 208000018737 Parkinson disease Diseases 0.000 abstract description 3
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- 230000036506 anxiety Effects 0.000 abstract description 2
- 206010015037 epilepsy Diseases 0.000 abstract description 2
- 230000001766 physiological effect Effects 0.000 abstract description 2
- 208000008238 Muscle Spasticity Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 208000018198 spasticity Diseases 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 46
- 235000018102 proteins Nutrition 0.000 description 39
- 238000004062 sedimentation Methods 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 25
- 102000037865 fusion proteins Human genes 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 21
- 238000000034 method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000012160 loading buffer Substances 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000003306 harvesting Methods 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000007995 HEPES buffer Substances 0.000 description 5
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 238000000749 co-immunoprecipitation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000004960 subcellular localization Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000003710 cerebral cortex Anatomy 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 2
- 101710137272 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 2
- 102100028327 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 Human genes 0.000 description 2
- 101710137274 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 3 Proteins 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 102000000470 PDZ domains Human genes 0.000 description 2
- 108050008994 PDZ domains Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000011095 buffer preparation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000027928 long-term synaptic potentiation Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229960002385 streptomycin sulfate Drugs 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 1
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102100033867 Protein TAMALIN Human genes 0.000 description 1
- 101710174537 Protein TAMALIN Proteins 0.000 description 1
- 241000973497 Siphonognathus argyrophanes Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 101150022630 prp5 gene Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004281 subthalamic nucleus Anatomy 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明涉及两个蛋白质mGluR5/CAL之间的相互作用的发现,以及发现CAL蛋白的细胞表达能促进mGluR5的表达,CAL蛋白不增加mGluR5基因的转录。本发明的重要之处,发现并证实了CAL和mGluR5之间特异性结合,并且CAL的细胞表达mGluR5的表达。这为探讨mGluR5在中枢神经系统发挥的生理学和病理学效应提供了新的理论依据,为治疗相关的疾病(帕金森病、痉挛、癫痫、抑郁、焦虑和疼痛)提供了新的潜在的药物作用靶标。The present invention relates to the discovery of the interaction between two proteins, mGluR 5 /CAL, and the discovery that the cellular expression of the CAL protein can promote the expression of mGluR 5 and that the CAL protein does not increase the transcription of the mGluR 5 gene. The important point of the present invention is to discover and confirm the specific binding between CAL and mGluR 5 , and the expression of mGluR 5 in CAL cells. This provides a new theoretical basis for exploring the physiological and pathological effects of mGluR 5 in the central nervous system, and provides new potential drugs for the treatment of related diseases (Parkinson's disease, spasticity, epilepsy, depression, anxiety and pain) target of action.
Description
技术领域:Technical field:
本发明利用组织内GST融合蛋白沉降、原核细胞内GST融合蛋白沉降、真核细胞内GST融合蛋白沉降、免疫共沉淀及细胞免疫荧光等技术发现并证实了CAL和代谢型谷氨酸受体-5(mGluR5)相互作用。并通过转染、Western Blot、RT-PCR等技术证实CAL蛋白的细胞表达能促进mGluR5的表达,推测了CAL促进mGluR5表达的可能性机制。对于阐述mGluR5在中枢神经系统中发挥作用提供了新的分子机制,为治疗相关神经系统疾病提供新的潜在的药物作用靶标。本发明涉及生物医学高技术中新方法、新蛋白的开发与应用领域。The present invention discovers and confirms CAL and metabotropic glutamate receptor- 5 (mGluR 5 ) interaction. And through transfection, Western Blot, RT-PCR and other techniques, it was confirmed that the expression of CAL protein can promote the expression of mGluR 5 , and the possible mechanism of CAL promoting the expression of mGluR 5 was speculated. It provides a new molecular mechanism for elucidating the role of mGluR 5 in the central nervous system, and provides a new potential drug target for the treatment of related nervous system diseases. The invention relates to the field of development and application of new methods and new proteins in biomedical high technology.
发明背景:Background of the invention:
mGluR5在纹状体、海马及大脑皮质区域大量表达。它经G蛋白,1、4、5-三磷酸肌醇(IP3)和Ca2+等细胞信号转导通路发挥重要的生物学效应,如参与调节中枢神经系统发育的可塑性、加强大脑皮质γ-氨基丁酸(GABA)能神经元的抑制性突触传递。在纹状体内,它可加强NMDA受体的神经毒性作用,并与底丘脑核及多巴胺(DA)系统发生联系,可能参与调节基底节的运动,并可能与帕金森病(PD)动物模型中锥体外系症状的产生有关。在海马内,mGluR5可形成长时程增强效应(LTP),与学习和记忆有关。此外,痉挛、癫痫、抑郁、焦虑与疼痛的发生都与mGluR5有密切的联系,但目前对mGluR5作用的分子调控机制仍不十分清晰。mGluR 5 is abundantly expressed in the striatum, hippocampus and cerebral cortex. It exerts important biological effects through G protein, 1, 4, 5-triphosphate inositol (IP 3 ) and Ca 2+ cell signal transduction pathways, such as participating in the regulation of the plasticity of central nervous system development, strengthening the cerebral cortex γ -Inhibitory synaptic transmission in aminobutyric acid (GABA)ergic neurons. In the striatum, it can strengthen the neurotoxic effect of NMDA receptors, and connect with the subthalamic nucleus and the dopamine (DA) system, may participate in the regulation of the movement of the basal ganglia, and may be associated with Parkinson's disease (PD) animal models Associated with extrapyramidal symptoms. In the hippocampus, mGluR 5 can form long-term potentiation (LTP), which is related to learning and memory. In addition, convulsions, epilepsy, depression, anxiety and pain are all closely related to mGluR 5 , but the molecular regulation mechanism of mGluR 5 is still not very clear.
很多GPCRs的羧基端含有可以和PDZ结构域相结合的区域。mGluR5属于GPCRs家族中的一员,其羧基末端也具有PDZ蛋白(含有PDZ结构域的蛋白质)的结合序列(PDZ bindingmotif):ST/SL序列。2002年Kitano J等人报道mGluR5可以与PDZ蛋白Tamalin特异性结合而促经mGluR5在细胞质膜上的表达。The carboxyl terminus of many GPCRs contains a region that can bind to a PDZ domain. mGluR 5 is a member of the GPCRs family, and its carboxy-terminus also has a PDZ binding motif (PDZ binding motif): ST/SL sequence. In 2002, Kitano J et al. reported that mGluR 5 can specifically bind to PDZ protein Tamalin to promote the expression of mGluR 5 on the plasma membrane.
在GPCRs的研究领域中,目前非G蛋白对受体的调控是研究的热点之一。本实验室的研究结果显示:肾上腺能受体(β1AR)可以与一些PDZ蛋白如MAGI-2、MAGI-3以及CAL(cystic fibrosis transmembrane conductance regulator associated ligand)特异性结合。其中MAGI-2可促进β1AR的减敏,MAGI-3能抑制β1AR所引起的MAPK的活化而CAL可以调节新合成β1AR在细胞内的运输。基于我们对β1AR的研究经验和Kitano J的报道,我们推测PDZ家族的其他成员也有可能与mGluR5相结合而调节其生理性质。In the research field of GPCRs, the regulation of receptors by non-G proteins is one of the hotspots. The research results of our laboratory show that: adrenergic receptor (β 1 AR) can specifically bind to some PDZ proteins such as MAGI-2, MAGI-3 and CAL (cystic fibrosis transmembrane conductance regulator a ssociated ligand ). Among them, MAGI-2 can promote the desensitization of β 1 AR, MAGI-3 can inhibit the activation of MAPK caused by β 1 AR, and CAL can regulate the transport of newly synthesized β 1 AR in cells. Based on our research experience on β 1 AR and the report of Kitano J, we speculate that other members of the PDZ family may also combine with mGluR 5 to regulate its physiological properties.
由于mGluR5在纹状体、海马及大脑皮质区域大量表达,我们利用mGluR5羧基末端的GST融合蛋白沉降脑组织蛋白裂解液。结果发现:GST-mGluR5-CT与GST阴性对照比较在75KD-58KD之间和75KD以上的位置能沉降出几种蛋白,提示mGluR5羧基末端可能与几种兔脑蛋白相结合。将样品经双向电泳分析,根据差异点的等电点和分子量,加上实验室前期工作基础上,我们推测在这几种蛋白质中可能存在CAL。沉降复合物用特异性的CAL抗体进行免疫印迹分析,结果显示mGluR5羧基末端可以与CAL相结合。Since mGluR 5 is abundantly expressed in the striatum, hippocampus and cerebral cortex, we used the GST fusion protein at the carboxy-terminal of mGluR 5 to sediment the brain tissue protein lysate. The results showed that compared with GST negative control, GST-mGluR 5 -CT could precipitate several proteins at the position between 75KD-58KD and above 75KD, suggesting that the carboxy terminus of mGluR 5 may bind to several rabbit brain proteins. The samples were analyzed by two-dimensional electrophoresis. According to the isoelectric point and molecular weight of the difference points, and on the basis of the previous work in the laboratory, we speculated that CAL may exist in these several proteins. The sedimentation complex was analyzed by immunoblotting with a specific CAL antibody, and the results showed that the carboxyl terminus of mGluR 5 could bind to CAL.
发明目的:Purpose of the invention:
通过组织内GST融合蛋白沉降筛选出与mGluR5相结合的PDZ蛋白:CAL。通过体外实验(GST-Pull down)与细胞内实验(免疫共沉淀)相结合,生化及分子生物学方法与形态学方法(细胞免疫荧光)相结合,来充分研究mGluR5与CAL的相互作用。在确定CAL/mGluR5相互作用后,继续研究CAL的细胞表达对mGluR5表达的影响,CAL蛋白不增加mGluR5基因的转录。The PDZ protein combined with mGluR 5 was screened by GST fusion protein sedimentation in tissues: CAL. The interaction between mGluR 5 and CAL was fully studied by combining in vitro experiments (GST-Pull down) with intracellular experiments (co-immunoprecipitation), biochemical and molecular biology methods and morphological methods (cellular immunofluorescence). After establishing the CAL/mGluR 5 interaction, the effect of cellular expression of CAL on mGluR 5 expression was continued, and the CAL protein did not increase the transcription of the mGluR 5 gene.
CAL和mGluR5相互作用并促进其表达对阐述mGluR5在中枢神经系统中发挥作用的分子机制提供了新的理论依据,为治疗相关神经系统疾病提供新的潜在的药物作用靶标。内容与要求:The interaction between CAL and mGluR 5 and the promotion of its expression provide a new theoretical basis for the elucidation of the molecular mechanism of mGluR 5 in the central nervous system, and provide new potential drug targets for the treatment of related nervous system diseases. Content and requirements:
CAL和mGluR5相互作用,CAL蛋白的细胞表达促进mGluR5的表达,而CAL蛋白不增加mGluR5基因的转录。这一发明涉及以下几个实验结果:CAL and mGluR 5 interact, and the cellular expression of CAL protein promotes the expression of mGluR 5 , while CAL protein does not increase the transcription of mGluR 5 gene. This invention involves the following experimental results:
1.GST-mGluR5对兔脑组织匀浆Pull-down考马斯亮蓝染色和免疫印迹分析结果,1. GST-mGluR 5 on rabbit brain tissue homogenate Pull-down Coomassie Brilliant Blue staining and Western blot analysis results,
2.GST-mGluR5对CAL的PDZ结构域Pull-down,2. Pull-down of GST-mGluR 5 on the PDZ domain of CAL,
3.GST-mGluR5对CAL完整蛋白质分子Pull-down,3. Pull-down of GST-mGluR 5 on the complete protein molecule of CAL,
4.mGluR5和CAL完整蛋白质分子在COS-7细胞的免疫共沉淀,4. Co-immunoprecipitation of intact protein molecules of mGluR 5 and CAL in COS-7 cells,
5.mGluR5和CAL完整蛋白质分子在BHK细胞的激光共聚焦亚细胞共定位,5. Confocal subcellular colocalization of mGluR 5 and CAL intact protein molecules in BHK cells,
6.CAL在COS-7中促进mGluR5表达的免疫印迹分析,6. Western blot analysis of CAL promoting mGluR 5 expression in COS-7,
7.CAL蛋白的细胞表达对mGluR5基因转录的影响。7. The effect of the cellular expression of CAL protein on the transcription of mGluR 5 gene.
以上所述及的实验内容和结果也即本发明的技术指标。The experimental content and results mentioned above are also the technical indicators of the present invention.
附图说明:Description of drawings:
图1.figure 1.
组织Pull-downOrganization Pull-down
A.考马斯亮兰染色结果,结果显示GST-mGluR5-CT与GST阴性对照比较在75KD-58KD之间和75KD以上的位置能沉降出几种蛋白。提示mGluR5羧基末端可能与几种兔脑蛋白相结合。A. Coomassie Brilliant Blue staining results, the results show that compared with GST negative control, GST-mGluR 5 -CT can precipitate several proteins at positions between 75KD-58KD and above 75KD. It suggested that the carboxy terminus of mGluR 5 may bind to several rabbit brain proteins.
B.用特异性抗体CAL免疫印迹分析,第1道为含CAL蛋白的兔脑组织裂解液上清,进行GST融合蛋白沉降实验后,在GST-mGluR5-CT的沉降复合物中能够检测到CAL蛋白的存在(第3道),在单独GST蛋白的沉降复合物中检测不到CAL(第2道)。显示mGluR5羧基末端与兔脑蛋白CAL相互作用,箭头所指为蛋白质CAL。B. Western blot analysis with specific antibody CAL, the first lane is the supernatant of rabbit brain tissue lysate containing CAL protein, after the GST fusion protein sedimentation experiment, it can be detected in the sedimentation complex of GST-mGluR 5 -CT Presence of CAL protein (lane 3), CAL was not detectable in the sedimented complex of GST protein alone (lane 2). It shows that the carboxyl terminus of mGluR 5 interacts with rabbit brain protein CAL, and the arrow points to the protein CAL.
图2.figure 2.
原核Pull-down分析结果,第1道为含His-CAL-PDZ融合蛋白的细菌裂解液上清,进行GST融合蛋白沉降实验后,在GST-mGluR5-CT-wt的沉降复合物中能够检测到His-CAL-PDZ蛋白的存在(第3道),在单独GST蛋白的沉降复合物中检测不到His-CAL-PDZ(第2道),当mGluR5羧基末端-1和-3位分别突变为丙氨酸时,在相应的GST-mGluR5-CT融合蛋白的沉降复合物中均检测不到His-CAL-PDZ蛋白的存在(第4道与第6道),当mGluR5羧基末端0和-2位分别突变为丙氨酸时,在相应的GST-mGluR5-CT融合蛋白的沉降复合物中均检测His-CAL-PDZ蛋白的存在(第5道与第7道)。说明mGluR5羧基末端-1和-3位突变能明显抑制其与CAL的结合。箭头所指的为His-CAL。Prokaryotic Pull-down analysis results, the first lane is the bacterial lysate supernatant containing His-CAL-PDZ fusion protein, after the GST fusion protein sedimentation experiment, it can be detected in the sedimentation complex of GST-mGluR 5 -CT-wt In the presence of His-CAL-PDZ protein (lane 3), His-CAL-PDZ was not detected in the sedimentation complex of GST protein alone (lane 2), when mGluR 5 carboxy-terminal -1 and -3 positions respectively When mutated to alanine, the presence of His-CAL-PDZ protein was not detected in the sedimentation complex of the corresponding GST-mGluR 5 -CT fusion protein (lanes 4 and 6), when mGluR 5 carboxy-terminal When
图3.image 3.
真核Pull-down分析结果,第1道为转染HA-CAL的细胞裂解液,在等量的转染HA-CAL的细胞裂解液进行GST融合蛋白沉降实验后,在GST-mGluR5-CT-wt的沉降复合物中能够检测到HA-CAL蛋白的存在(第3道),在单独GST蛋白的沉降复合物中检测不到HA-CAL(第2道),当mGluR5羧基末端最后一个氨基酸Ser突变为Ala时,在相应的GST-mGluR5-CT融合蛋白的沉降复合物中检测不到CAL蛋白的存在(第4道)。说明mGluR5羧基末端能与CAL蛋白完整的蛋白质分子发生作用,并且mGluR5羧基末端的突变能明显抑制其与CAL的结合。箭头所指的为HA-CAL。Eukaryotic Pull-down analysis results, the first lane is the cell lysate transfected with HA-CAL, after the same amount of HA-CAL transfected cell lysate was subjected to the GST fusion protein sedimentation experiment, the GST-mGluR 5 -CT The presence of HA-CAL protein could be detected in the sedimentation complex of -wt (lane 3), HA-CAL was not detected in the sedimentation complex of GST protein alone (lane 2), when the mGluR 5 carboxy-terminal last When the amino acid Ser was mutated to Ala, the presence of CAL protein was not detectable in the sedimentation complex of the corresponding GST-mGluR 5 -CT fusion protein (lane 4). It shows that the mGluR 5 carboxy terminus can interact with the complete protein molecule of CAL protein, and the mutation of mGluR 5 carboxyl terminus can obviously inhibit its combination with CAL. The arrow points to HA-CAL.
图4.Figure 4.
免疫共沉淀分析完整蛋白质分子mGluR5和CAL的相互作用。Co-immunoprecipitation analysis of the interaction of the intact protein molecule mGluR 5 and CAL.
图B第2道为单独转染HA-CAL的细胞裂解液,图B和C第3道为共转染HA-CAL和Flag-mGluR5的细胞裂解液。在单独转染HA-CAL的细胞内,免疫沉淀复合物中检测不到HA-CAL蛋白(A第2道);在空白细胞COS-7内,免疫沉淀复合物中检测不到HA-CAL蛋白(A第1道);而在共转染HA-CAL和Flag-mGluR5的细胞内,可在其免疫沉淀复合物中检测到HA-CAL(第3道)。这表明在细胞内完整的CAL蛋白能与mGluR5发生相互作用。Lane 2 in Figure B is the cell lysate transfected with HA-CAL alone, and Lane 3 in Figures B and C is the cell lysate co-transfected with HA-CAL and Flag-mGluR 5 . In cells transfected with HA-CAL alone, HA-CAL protein was not detected in the immunoprecipitation complex (A, lane 2); in the blank cell COS-7, HA-CAL protein was not detected in the immunoprecipitation complex (A lane 1); while in cells co-transfected with HA-CAL and Flag-mGluR 5 , HA-CAL could be detected in its immunoprecipitated complex (lane 3). This indicates that the intact CAL protein can interact with mGluR 5 in cells.
图5.Figure 5.
免疫荧光激光共聚焦共定位Immunofluorescence confocal confocal localization
a.mGluR5单独转染在BHK亚细胞定位 b.CAL单独转染在BHK亚细胞定位a.mGluR 5 alone transfected in BHK subcellular localization b.CAL alone transfected in BHK subcellular localization
c.mGluR5在CAL存在条件下在BHK亚细胞定位 d.CAL在mGluR5存在条件下在BHK亚细胞定位c. mGluR 5 subcellular localization in BHK in the presence of CAL d. subcellular localization of CAL in BHK in the presence of mGluR 5
e.CAL与mGluR5在BHK亚细胞共定位e. CAL and mGluR 5 co-localize in BHK subcells
图6.Figure 6.
随着细胞内CAL增加,mGluR5也随之增加。经过统计学分析(9B)显示:0.60ug组与对照组相比,两组间的差异有显著性统计学意义(**P<0.01,n=4);0.15ug组、0.30ug、1.20ug组与对照组相比,两组间的差异有统计学意义(*P<0.05,n=4)。表明CAL能增加mGluR5蛋白的表达水平。As intracellular CAL increases, so does mGluR5 . After statistical analysis (9B), it showed that: compared with the control group, the difference between the 0.60ug group and the control group was statistically significant (**P<0.01, n=4); 0.15ug group, 0.30ug, 1.20ug Compared with the control group, the difference between the two groups was statistically significant (*P<0.05, n=4). It shows that CAL can increase the expression level of mGluR 5 protein.
图7.Figure 7.
A图:提取的细胞总RNA,第一道为-/pCDNA3-Flag-mGluR5组总RNA,第二道为pBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5组总RNA。Panel A: total RNA extracted from cells, the first lane is the total RNA of -/pCDNA 3 -Flag-mGluR 5 group, the second lane is the total RNA of pBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 group.
B图:第一、三道分别为-/pCDNA3-Flag-mGluR5、pBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5组β-actin PCR产物,第二、四道分别为-/pCDNA3-Flag-mGluR5、pBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5组mGluR5PCR产物。Panel B: the first and third lanes are respectively -/pCDNA 3 -Flag-mGluR 5 , pBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 groups of β-actin PCR products, the second and fourth lanes are respectively - /pCDNA 3 -Flag-mGluR 5 , pBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 group mGluR 5 PCR products.
C图:pBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5组细胞内mGluR5的RNA水平低于-/pCDNA3-Flag-mGluR5组。统计学分析显示,两组之间的差异有显著性统计学意义(*P<0.05,n=3)。Panel C: the RNA level of mGluR 5 in the pBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 group was lower than that in the -/pCDNA 3 -Flag-mGluR 5 group. Statistical analysis showed that the difference between the two groups was statistically significant ( * P<0.05, n=3).
实施例:Example:
1.GST-mGluR5-CT融合蛋白筛选兔脑组织中与其相结合的PDZ蛋白1. GST-mGluR 5 -CT fusion protein screening of PDZ protein bound to it in rabbit brain tissue
1.1脑蛋白制备:1.1 Brain protein preparation:
1)取健康雌性新西兰兔,用手术剪将头部切除,用骨钳剥离兔脑。将兔脑放在冰上,用PBS将脑组织清洗干净,然后剪成组织碎块,称湿重。1) Take a healthy female New Zealand rabbit, cut off the head with surgical scissors, and peel off the rabbit brain with bone forceps. Put the rabbit brain on ice, wash the brain tissue with PBS, cut it into pieces, and weigh the wet weight.
2)匀浆:将组织放入匀浆器并以100mg/ml比例加入组织裂解液。手动匀浆。注意尽量保持低温,快速匀浆。2) Homogenization: Put the tissue into a homogenizer and add tissue lysate at a ratio of 100 mg/ml. Homogenize manually. Pay attention to keep the temperature as low as possible and homogenate quickly.
3)12000rpm离心,4℃,20min。3) Centrifuge at 12000rpm, 4°C, 20min.
4)取少量上清进行定量。4) Take a small amount of supernatant for quantification.
组织裂解液的配制方法:Preparation method of tissue lysate:
HEPES 10mMHEPES 10mM
NaCl 50mMNaCl 50mM
EDTA 5mMEDTA 5mM
Triton X-100 1.0%Triton X-100 1.0%
Benzamidine 1mMBenzamidine 1mM
1.2GST-融合蛋白诱导与纯化:1.2 GST-fusion protein induction and purification:
1.2.1GST-融合蛋白诱导表达1.2.1 Induced expression of GST-fusion protein
1)将构建的GST融合蛋白表达质粒转化到大肠杆菌BL-21中,挑单克隆菌株接种到5-10ml LB培养液中(根据菌株抗性加入相应抗生素),在37℃摇床内以250rpm/min摇菌过夜。1) Transform the constructed GST fusion protein expression plasmid into Escherichia coli BL-21, pick a single clone strain and inoculate it into 5-10ml LB culture medium (add corresponding antibiotics according to the strain resistance), and inoculate in a shaker at 37°C at 250rpm /min Shake the bacteria overnight.
2)取3ml菌液接种到1L的LB培养液中(根据菌株的抗性加入相应的抗生素),在37℃摇床内以250rpm/min摇菌2-3h,间断性测菌液OD600吸光度值至0.6-0.7之间为最佳。2) Inoculate 3ml of bacterial solution into 1L of LB culture medium (add corresponding antibiotics according to the resistance of the strain), shake the bacteria at 250rpm/min in a shaker at 37°C for 2-3 hours, and measure the OD 600 absorbance of the bacterial solution intermittently The best value is between 0.6-0.7.
3)加入IPTG(终浓度达到500μmol/L)在37℃摇床内以250rpm/min诱导细菌生长2h。3) Add IPTG (final concentration reaches 500 μmol/L) to induce bacterial growth for 2 hours in a shaker at 37° C. at 250 rpm/min.
4)收集培养液:4℃,以3000rpm离心30min,弃去上清,保留沉淀。4) Collect the culture medium: centrifuge at 3000 rpm for 30 min at 4°C, discard the supernatant, and keep the precipitate.
5)沉淀中加入25ml预先配制的预冷的Harvest buffer液重悬菌体,超声破菌(输出功率10w,总计10-15分钟,脉冲1次/1.5s)。于4℃以15000rpm离心20min,上清移至新的高速离心管中。取部分上清加入等量的2×蛋白上样缓冲液混匀,95℃ 5min后取出适量样品进行SDS-PAGE电泳考马斯亮蓝染色。5) Add 25ml pre-prepared pre-cooled Harvest buffer to resuspend the bacteria, and ultrasonically break the bacteria (output power 10w, total 10-15 minutes,
1.2.2GST-融合蛋白鉴定(考马斯亮蓝染色)1.2.2 Identification of GST-fusion protein (Coomassie brilliant blue staining)
(1)蛋白样品经SDS-PAGE。(1) Protein samples were subjected to SDS-PAGE.
(2)将PAGE胶放入染色液中,室温轻摇1h。(2) Put the PAGE gel into the staining solution and shake gently at room temperature for 1 hour.
(3)然后将胶放入脱色液中轻摇,直至胶的背景变为白色即可。(3) Then put the glue into the decolorization solution and shake until the background of the glue turns white.
(4)将胶应用干胶仪干燥后保存。(4) Dry the glue with a glue dryer and save it.
试剂的配制:Preparation of reagents:
(1)考马斯亮蓝染色液:(1L/1×)(1) Coomassie brilliant blue staining solution: (1L/1×)
Coomassie Blue R250 1gCoomassie Blue R250 1g
去离子水 500mlDeionized water 500ml
乙酸 100mlAcetic acid 100ml
甲醇 400mlMethanol 400ml
(2)脱色液: (1L/1×)(2) Decolorizing solution: (1L/1×)
去离子水 500mlDeionized water 500ml
乙酸 100mlAcetic acid 100ml
甲醇 400mlMethanol 400ml
1.2.3GST-融合蛋白纯化1.2.3 GST-fusion protein purification
1)鉴定蛋白表达成功后进行蛋白纯化,加入硫酸链霉素(10mg/L)混匀,于4℃15000rpm离心20min,上清移至另一新的低速离心管中。1) After identifying the successful expression of the protein, perform protein purification, add streptomycin sulfate (10mg/L) and mix well, centrifuge at 15000rpm at 4°C for 20min, and transfer the supernatant to another new low-speed centrifuge tube.
2)加入Glutathione-Sepharose 4B 60mg,4℃上下颠倒孵育3h。2) Add Glutathione-Sepharose 4B 60mg, and incubate upside down at 4°C for 3h.
3)4℃,3000rpm/min离心1min,吸弃上清,再加入30ml冰预冷的Harvest buffer液混匀后再离心(4℃,3000rpm/min,离心1min)。3) Centrifuge at 3000rpm/min at 4°C for 1min, discard the supernatant, add 30ml of ice-cold Harvest buffer, mix well and then centrifuge (4°C, 3000rpm/min, 1min at 3000rpm).
4)重复上述步骤(3)两次。4) Repeat the above step (3) twice.
5)最后用1ml Harvest buffer重悬Glutathione-Sepharose 4B。5) Finally, resuspend Glutathione-Sepharose 4B with 1ml Harvest buffer.
6)取50μl上述样品加入50μl 2×蛋白上样缓冲液混匀,置于95℃5min后取出适量样品进行蛋白纯化后的SDS-PAGE电泳考马斯亮蓝染色鉴定蛋白纯化的效果。6) Take 50 μl of the above sample and add 50 μl of 2× protein loading buffer to mix, place at 95°C for 5 minutes, take out an appropriate amount of sample for protein purification, SDS-PAGE electrophoresis and Coomassie brilliant blue staining to identify the effect of protein purification.
Harvest buffer配制的方法: 总体积25mlHarvest buffer preparation method: Total volume 25ml
HEPES液 (1mol/l pH7.4) 250μlHEPES solution (1mol/l pH7.4) 250μl
Nacl液 (1mol/l) 1.25mlNacl solution (1mol/l) 1.25ml
Benzamidine 0.004gBenzamidine 0.004g
EDTA液 (0.5mol/l PH8.0) 250μlEDTA solution (0.5mol/l PH8.0) 250μl
H2O 23.25mlH 2 O 23.25ml
1.3GST融合蛋白沉降实验:1.3 GST fusion protein sedimentation experiment:
1)取等量结合于Glutathione-Sepharose 4B的GST及GST-mGluR5-CT融合蛋白,加入1ml脑蛋白上清,于4℃旋转孵育3h。1) Take an equal amount of GST and GST-mGluR5-CT fusion proteins bound to Glutathione-Sepharose 4B, add 1ml of cerebroprotein supernatant, and incubate at 4°C for 3h with rotation.
2)3000rpm 4℃2min离心收集Glutathione-Sepharose 4B,小心吸弃上清,留沉淀。2) Collect Glutathione-Sepharose 4B by centrifugation at 3000rpm at 4°C for 2min, carefully discard the supernatant and keep the precipitate.
3)沉淀物加入1ml Wash Buffer I,轻轻混匀3000rpm 4℃2min,小心吸弃上清,留沉淀。3) Add 1ml Wash Buffer I to the precipitate, mix gently at 3000rpm 4°C for 2min, carefully discard the supernatant, and keep the precipitate.
4)重复步骤3)三次。4) Repeat step 3) three times.
5)沉淀物加入1ml Wash Buffer II,轻轻混匀3000rpm 4℃2min,小心吸弃上清,留沉淀。5) Add 1ml Wash Buffer II to the precipitate, mix gently at 3000rpm 4°C for 2min, carefully discard the supernatant, and keep the precipitate.
6)在沉降复合物中加入适量的蛋白电泳上样缓冲液,95℃5min,离心后取上清。样品经SDS-PAGE后,进行考马斯亮蓝染色与免疫印迹分析。6) Add an appropriate amount of protein electrophoresis loading buffer to the sedimentation complex, centrifuge at 95° C. for 5 minutes, and take the supernatant. After the samples were subjected to SDS-PAGE, Coomassie brilliant blue staining and western blot analysis were performed.
Wash Buffer I:Wash Buffer I:
HEPES 10mMHEPES 10mM
NaCl 50-100mMNaCl 50-100mM
EDTA 5mMEDTA 5mM
Tween20 0.1%Tween20 0.1%
BSA 3gBSA 3g
Benzamidine 1mM(使用前临时加入)Benzamidine 1mM (temporarily added before use)
Wash Buffer II:Wash Buffer II:
HEPES 10mMHEPES 10mM
NaCl 50-100mMNaCl 50-100mM
EDTA 5mMEDTA 5mM
Tween20 0.1%Tween20 0.1%
Benzamidine 1mM(使用前临时加入)Benzamidine 1mM (temporarily added before use)
1.3.1考马斯亮蓝染色沉降复合物样品(具体方法见1.2.2)1.3.1 Coomassie Brilliant Blue staining sedimentation complex samples (see 1.2.2 for specific methods)
1.3.2免疫印迹分析沉降复合物样品:1.3.2 Western blot analysis of sedimentation complex samples:
(1)样品经SDS-PAGE,转移至硝酸纤维素膜上。(1) The sample was transferred to a nitrocellulose membrane by SDS-PAGE.
(2)用封闭液室温封闭1h,TBST洗膜三次,每次10min。(2) Block with blocking solution for 1 h at room temperature, wash the membrane three times with TBST, 10 min each time.
(3)加入用抗体稀释液稀释的一抗(anti-PIST,1∶1000),室温轻摇1h,TBST洗膜三次,每次10min。(3) Add the primary antibody (anti-PIST, 1:1000) diluted with antibody diluent, shake gently at room temperature for 1 h, and wash the membrane three times with TBST, 10 min each time.
(4)加入用抗体稀释液稀释的HRP标记的二抗(1∶3000),室温轻摇1h,TBST洗膜三次,每次10min。(4) Add HRP-labeled secondary antibody (1:3000) diluted with antibody diluent, shake gently at room temperature for 1 h, and wash the membrane three times with TBST, 10 min each time.
(5)ECL试剂盒显色3min,X-光片显影。(5) ECL kit develops color for 3 minutes, and X-ray film develops.
2.原核细胞内GST融合蛋白沉降实验2. GST fusion protein sedimentation experiment in prokaryotic cells
2.1His融合蛋白的诱导表达及鉴定:2.1 Induced expression and identification of His fusion protein:
1)将重组表达质粒His-CAL-PDZ转化到大肠杆菌BL-21(DE3)中,挑单克隆菌株接种到5-10ml LB培养液中(根据菌株抗性加入相应抗生素),在37℃摇床内以250rpm/min摇菌过夜。1) Transform the recombinant expression plasmid His-CAL-PDZ into Escherichia coli BL-21(DE3), inoculate the single clone strain into 5-10ml LB culture medium (add corresponding antibiotics according to the strain resistance), shake at 37°C The bacteria were shaken overnight at 250rpm/min in the bed.
2)取3ml菌液接种到1L的LB培养液中(根据菌株的抗性加入相应的抗生素),在37℃摇床内以250rpm/min摇菌2-3h,间断性测菌液OD600吸光度值,至0.6-0.7之间为最佳。2) Inoculate 3ml of bacterial solution into 1L of LB culture medium (add corresponding antibiotics according to the resistance of the strain), shake the bacteria at 250rpm/min in a shaker at 37°C for 2-3 hours, and measure the OD 600 absorbance of the bacterial solution intermittently The value is best between 0.6-0.7.
3)加入IPTG(终浓度达到500μmol/L),在37℃摇床内以250rpm/min诱导细菌生长2h。3) Add IPTG (final concentration reaches 500 μmol/L), and induce bacterial growth in a shaker at 37° C. at 250 rpm/min for 2 hours.
4)4℃,3000rpm离心30min收菌,弃上清,留沉淀。4) Harvest the bacteria by centrifuging at 3000 rpm for 30 minutes at 4°C, discard the supernatant and keep the precipitate.
5)沉淀中加入25ml预先配制的预冷的Harvest buffer液重悬菌体,超声破菌(输出功率10w,总计10-15分钟,脉冲1次/1.5s)。于4℃以15000rpm离心20min,上清移至新的高速离心管中。取部分上清加入等量的2×蛋白上样缓冲液混匀,95℃5min后取出适量样品进行SDS-PAGE电泳考马斯亮蓝染色鉴定。5) Add 25ml pre-prepared pre-cooled Harvest buffer to resuspend the bacteria, and ultrasonically break the bacteria (output power 10w, total 10-15 minutes,
2.2GST融合蛋白沉降实验:2.2 GST fusion protein sedimentation experiment:
(1)取等量经IPTG诱导表达的含His-CAL-PDZ的细菌裂解液上清。(1) Take an equal amount of bacterial lysate supernatant containing His-CAL-PDZ induced by IPTG.
(2)分别加入等量结合于Glutathione-Sepharose 4B的GST及GST-mGluR5-CT及其四个突变体的融合蛋白,于4℃旋转孵育2h。(2) Equal amounts of GST bound to Glutathione-Sepharose 4B, GST-mGluR 5 -CT and fusion proteins of four mutants thereof were added, and incubated at 4° C. for 2 h with rotation.
(3)离心收集Glutathione-Sepharose 4B,按1.3的方法充分洗涤。(3) Collect Glutathione-Sepharose 4B by centrifugation, and wash thoroughly according to the method in 1.3.
(4)在沉降复合物中加入适量的蛋白电泳上样缓冲液,95℃加热5min,然后离心后取上清,得到免疫印迹分析样品。(4) Add an appropriate amount of protein electrophoresis loading buffer to the sedimentation complex, heat at 95° C. for 5 min, and then centrifuge to obtain the supernatant to obtain a sample for western blot analysis.
(5)将样品进行免疫印迹分析,具体方法参见1.3.2,一抗为anti-His(1∶1000)。(5) The samples were subjected to Western blot analysis, see 1.3.2 for specific methods, and the primary antibody was anti-His (1:1000).
3.真核细胞内GST融合蛋白沉降实验3. GST fusion protein sedimentation experiment in eukaryotic cells
3.1细胞准备:3.1 Cell preparation:
COS-7细胞在完全培养基(高糖DMEM,10%胎牛血清,1%青霉素,1%硫酸链霉素)37℃、5%CO2恒温培养箱中培养。COS-7 cells were cultured in a complete medium (high glucose DMEM, 10% fetal calf serum, 1% penicillin, 1% streptomycin sulfate) in a constant temperature incubator at 37°C and 5% CO 2 .
3.2转染:3.2 Transfection:
转染前将细胞接种至塑料平皿中,在光镜下观察细胞,当细胞密度占培养皿生长表面70%-80%时转染。根据实验目的不同,所需DNA的量不同。Before transfection, the cells were inoculated into a plastic plate, observed under a light microscope, and transfected when the cell density accounted for 70%-80% of the growth surface of the culture plate. Depending on the purpose of the experiment, the amount of DNA required varies.
具体步骤:Specific steps:
(1)稀释DNA:若转染90mm平皿用250ul0.9%NaCl稀释;若转染至6-Well板用100ul0.9%NaCl稀释;轻轻震荡混匀,静置5min。(1) Dilution of DNA: Dilute with 250ul 0.9% NaCl if transfected into a 90mm plate; dilute with 100ul 0.9% NaCl if transfected into a 6-Well plate; shake gently to mix, and let stand for 5min.
(2)稀释Hifectin II:按1ugDNA∶2ul Hifectin II的比例将Hifectin II用0.9%NaCl稀释;轻轻震荡混匀,静置5min。(2) Dilute Hifectin II: Dilute Hifectin II with 0.9% NaCl according to the ratio of 1ugDNA: 2ul Hifectin II; shake gently to mix and let stand for 5min.
(3)将稀释Hifectin II加到稀释DNA,轻轻震荡混匀,静置20min。(3) Add the diluted Hifectin II to the diluted DNA, vortex gently to mix, and let stand for 20 minutes.
(4)同时将培养皿中的培养基换为新鲜无血清培养基。(4) At the same time, replace the medium in the culture dish with fresh serum-free medium.
(5)放在37℃、5%CO2恒温培养箱中培养,4h后换成完全培养基。(5) Culture in a constant temperature incubator at 37°C and 5% CO 2 , and replace with complete medium after 4 hours.
(6)CO2恒温培养箱37℃继续培养24-48小时表达基因。(6) Continue culturing in a CO 2 constant temperature incubator at 37°C for 24-48 hours to express the gene.
3.3GST融合蛋白沉降实验:3.3 GST fusion protein sedimentation experiment:
3.3.1细胞蛋白的提取:3.3.1 Extraction of cell protein:
1)去培养液后用温热的PBS冲洗2~3遍(冷的PBS有可能使细胞脱落)。1) After removing the culture medium, rinse with warm PBS 2 to 3 times (cold PBS may cause the cells to fall off).
2)90mm培养皿中加入1ml的冰预冷的裂解液后置于冰上2-5min。2) Add 1ml of ice-precooled lysate to a 90mm petri dish and put it on ice for 2-5min.
3)用细胞刮刮下细胞,4℃,上下颠倒混匀30min。3) Scrape the cells with a cell scraper, and mix them upside down for 30 minutes at 4°C.
4)12000rpm离心,4℃,15min,取上清至新鲜高压灭菌的1.5ml EP中。4) Centrifuge at 12000rpm at 4°C for 15min, and transfer the supernatant to 1.5ml EP sterilized by fresh autoclaving.
细胞裂解液的配制方法:Preparation method of cell lysate:
HEPES 10mMHEPES 10mM
NaCl 50mMNaCl 50mM
EDTA 5mMEDTA 5mM
Triton X-100 1.0%Triton X-100 1.0%
Benzamidine 1mM(使用前临时加入)Benzamidine 1mM (temporarily added before use)
3.3.2GST融合蛋白沉降实验:3.3.2 GST fusion protein sedimentation experiment:
1)取等量经瞬时转染表达含HA-CAL的细胞裂解液上清。1) Take an equal amount of supernatant of cell lysate expressing HA-CAL through transient transfection.
2)分别加入等量结合于Glutathione-Sepharose 4B的GST及GST-mGluR5-CT及其突变体SSSA的融合蛋白,于4℃旋转孵育2h。2) Equal amounts of GST bound to Glutathione-Sepharose 4B, fusion protein of GST-mGluR 5 -CT and its mutant SSSA were added respectively, and incubated at 4° C. for 2 hours with rotation.
3)离心收集Glutathione-Sepharose 4B,按1.3的方法充分洗涤。3) Collect Glutathione-Sepharose 4B by centrifugation, and wash thoroughly according to the method in 1.3.
4)在沉降复合物中加入适量的蛋白电泳上样缓冲液,95℃加热5min,然后离心后取上清,得到免疫印迹分析样品。4) Add an appropriate amount of protein electrophoresis loading buffer to the sedimentation complex, heat at 95° C. for 5 minutes, and then centrifuge to obtain the supernatant to obtain a sample for western blot analysis.
5)将样品进行免疫印迹分析,具体方法参见1.3.2,一抗为anti-HA(1∶1000)。5) The samples were subjected to Western blot analysis, see 1.3.2 for specific methods, and the primary antibody was anti-HA (1:1000).
4.免疫共沉淀4. Co-immunoprecipitation
4.1.细胞培养及转染4.1. Cell culture and transfection
COS-7细胞在含10%胎牛血清及1%青霉素和链霉素的DMEM(高糖)培养基中,于37℃,5%CO2的培养箱中培养。将-/PBK-CMV-HA-CAL以及PBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5转染密度适宜的COS-7细胞,转染试剂为Hifectin II,具体方法参见3.2。COS-7 cells were cultured in DMEM (high glucose) medium containing 10% fetal bovine serum and 1% penicillin and streptomycin at 37°C in an incubator with 5% CO 2 . COS-7 cells with appropriate density were transfected with -/PBK-CMV-HA-CAL and PBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 , and the transfection reagent was Hifectin II. For specific methods, see 3.2.
4.2.细胞蛋白的提取:具体方法见3.3.14.2. Extraction of cell protein: see 3.3.1 for specific methods
4.3免疫共沉淀4.3 Co-immunoprecipitation
1)取上清,留取少量作免疫印迹对照,1ml蛋白上清液中加入30μl anti-Flag M2 affinitygel,4℃旋转孵育2h。1) Take the supernatant, keep a small amount for immunoblotting control, add 30μl anti-Flag M2 affinitygel to 1ml protein supernatant, and incubate at 4°C for 2h with rotation.
2)3000rpm离心,4℃,1min收集免疫沉淀复合物按,1.3的方法充分洗涤。2) Centrifuge at 3000rpm at 4°C for 1 min to collect the immunoprecipitated complex and wash thoroughly according to the method in 1.3.
3)在沉降复合物中加入适量的蛋白电泳上样缓冲液,95℃加热5min,然后离心后取上清,得到免疫印迹分析样品。3) Add an appropriate amount of protein electrophoresis loading buffer to the sedimentation complex, heat at 95° C. for 5 minutes, and then centrifuge to collect the supernatant to obtain samples for western blot analysis.
4)将样品进行免疫印迹分析,具体方法参见1.3.2,一抗为anti-HA(1∶1000)4) Perform Western blot analysis on the samples, see 1.3.2 for specific methods, the primary antibody is anti-HA (1:1000)
5.细胞免疫荧光5. Cell Immunofluorescence
5.1玻璃爬片的处理:5.1 Treatment of glass climbing pieces:
将盖玻片置入浓酸中浸泡2小时,用去离子水洗净后室温干燥。将经酸处理过的盖玻片投入十倍稀释的多聚赖氨酸溶液中,室温放置5min后取出于60℃干燥1小时或室温过夜。用前将盖玻片浸泡于75%乙醇中至少30min。The coverslips were soaked in concentrated acid for 2 hours, washed with deionized water and dried at room temperature. Put the acid-treated coverslip into ten-fold diluted poly-lysine solution, leave it at room temperature for 5 minutes, take it out and dry it at 60°C for 1 hour or overnight at room temperature. Soak coverslips in 75% ethanol for at least 30 min before use.
5.2细胞培养及转染5.2 Cell culture and transfection
BHK细胞接种至玻璃爬片上在含10%胎牛血清及1%青霉素和链霉素的DMEM(高糖)培养基中,于37℃,5%CO2的培养箱中培养。当细胞达到适宜的密度时将-/PBK-CMV-HA-CAL、PBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5转染至BHK细胞,转染试剂为Hifectin II,具体方法参见3.2。BHK cells were inoculated onto glass slides and cultured in DMEM (high glucose) medium containing 10% fetal bovine serum and 1% penicillin and streptomycin in an incubator at 37°C and 5% CO 2 . When the cells reach an appropriate density, transfect -/PBK-CMV-HA-CAL, PBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 into BHK cells, and the transfection reagent is Hifectin II. For details, see 3.2 .
5.3细胞免疫荧光染色5.3 Immunofluorescent staining of cells
(1)细胞固定:转染后36h用D-PBS清洗细胞3次,每次5分钟,取出盖玻片,用滤纸将残留液体吸干,用4%多聚甲醛室温固定30分钟。(1) Cell fixation: 36 hours after transfection, the cells were washed 3 times with D-PBS, 5 minutes each time, the coverslip was taken out, the residual liquid was blotted dry with filter paper, and fixed with 4% paraformaldehyde at room temperature for 30 minutes.
(2)2%BSA/D-PBS漂洗细胞3次,每次5分钟。(2) Rinse the cells with 2% BSA/D-PBS 3 times, 5 minutes each time.
(3)细胞透化:室温下,用Saponin缓冲液室温孵育30分钟。(3) Cell permeabilization: at room temperature, incubate with Saponin buffer at room temperature for 30 minutes.
(4)一抗孵育:将盖玻片有细胞的一面朝上,用Saponin缓冲液(anti-HA 1∶100anti-Flag1∶250)稀释一抗并点在盖玻片上(如过进行双免疫荧光分析则同时加入两种一抗),室温1小时或4℃过夜。(4) Primary antibody incubation: place the cell side of the coverslip facing up, dilute the primary antibody with Saponin buffer (anti-HA 1:100anti-Flag1:250) and spot on the coverslip (for double immunization as before) For fluorescence analysis, add two kinds of primary antibodies at the same time), at room temperature for 1 hour or at 4°C overnight.
(5)用Saponin缓冲液清洗细胞3次,每次5分钟。(5) Wash the cells 3 times with Saponin buffer, 5 minutes each time.
(6)孵育二抗:将盖玻片有细胞的一面朝上,用Saponin缓冲液稀释二抗(FITC标记山羊抗兔IgG 1∶100,罗丹明标记山羊抗大鼠IgG 1∶100)并点在盖玻片上(如过进行双免疫荧光分析则同时加入两种二抗),室温30分钟。(6) Incubate the secondary antibody: place the cell side of the coverslip upward, dilute the secondary antibody with Saponin buffer (FITC-labeled goat anti-rabbit IgG 1:100, rhodamine-labeled goat anti-rat IgG 1:100) and Spot on the coverslip (if performing double immunofluorescence analysis, add two secondary antibodies at the same time), room temperature for 30 minutes.
(7)D-PBS清洗细胞3次,每次5分钟。(7) Wash the cells with D-PBS 3 times, 5 minutes each time.
(8)封片:取15ul封片剂滴在载玻片上,将盖玻片有细胞的一面朝下封片。有关缓冲液的配制:(8) Mounting: Take 15ul of mounting medium and drop it on the glass slide, and seal the cover slip with the cell side facing down. Regarding buffer preparation:
(1)浓酸:浓硝酸∶浓盐酸=2∶1(V/V)(1) concentrated acid: concentrated nitric acid: concentrated hydrochloric acid = 2:1 (V/V)
(2)D-PBS(PH:7.4 1L/1×):NaCl: 8.0g(2) D-PBS (PH: 7.4 1L/1×): NaCl: 8.0g
KCl: 0.2gKCl: 0.2g
MgCl2·6H2O: 0.1gMgCl 2 6H 2 O: 0.1g
Na2HPO4·12H2O: 2.90gNa 2 HPO 4 ·12H 2 O: 2.90g
CaCl2: 0.1g CaCl2 : 0.1g
KH2HPO4: 0.2g KH2HPO4 : 0.2g
(3)封闭液:2%BSA/D-PBS(3) Blocking solution: 2% BSA/D-PBS
(4)透化液:Saponin Buffer(2%BSA/D-PBS/0.04%Saponin)(4) Permeabilization solution: Saponin Buffer (2% BSA/D-PBS/0.04% Saponin)
(5)4%多聚甲醛固定液:60ml D-PBS中加入4g多聚甲醛,在60-80℃水浴中滴加1mol/ml的NaOH至溶解透明。待溶液冷却至15℃时用HCl将PH调至7.0。最后用D-PBS定容至100ml。(5) 4% paraformaldehyde fixative solution: add 4g paraformaldehyde to 60ml D-PBS, add 1mol/ml NaOH dropwise in a water bath at 60-80°C until dissolved and transparent. When the solution was cooled to 15°C, the pH was adjusted to 7.0 with HCl. Finally, dilute to 100ml with D-PBS.
(6)封片剂:用D-PBS制备70%的甘油(6) Mounting agent: prepare 70% glycerol with D-PBS
6.CAL促进mGluR5蛋白表达的实验6. The experiment of CAL promoting the expression of mGluR 5 protein
6.1.细胞培养及转染:6.1. Cell culture and transfection:
(1)COS-7细胞在含10%胎牛血清及1%青霉素和链霉素的DMEM(高糖)培养基中,于37℃、5%CO2的培养箱中培养。(1) COS-7 cells were cultured in a DMEM (high glucose) medium containing 10% fetal bovine serum and 1% penicillin and streptomycin in an incubator at 37°C and 5% CO 2 .
(2)将COS-7细胞接种至35ml的细胞培养皿中,当细胞密度达到80%左右时,将不同剂量的pBK-CMV-HA-CAL质粒(0、0.15、0.30、0.60、1.20ug)分别和相同剂量pCDNA3-Flag-mGluR5(0.5ug)共同转染COS-7细胞,转染试剂为HifectinII,具体方法参见3.2。(2) Inoculate COS-7 cells into a 35ml cell culture dish, and when the cell density reaches about 80%, different doses of pBK-CMV-HA-CAL plasmid (0, 0.15, 0.30, 0.60, 1.20ug) COS-7 cells were co-transfected with the same dose of pCDNA 3 -Flag-mGluR 5 (0.5ug), respectively, and the transfection reagent was HifectinII. For specific methods, see 3.2.
6.2收集细胞样品:6.2 Collection of cell samples:
1)转染后36小时,收集细胞样品。1) 36 hours after transfection, cell samples were collected.
2)弃去旧的细胞培养基,用温热的PBS清洗细胞两次。将培养皿倒扣到滤纸上,取出残留的PBS。2) Discard the old cell culture medium and wash the cells twice with warm PBS. Invert the Petri dish onto the filter paper to remove residual PBS.
3)加入200ul1.5×蛋白上样缓冲液,用细胞刮刮下细胞至1.5mlEP管。3) Add 200ul of 1.5× protein loading buffer, and scrape the cells with a cell scraper into a 1.5ml EP tube.
4)超声(100~200w)3s,2次。4) Ultrasound (100-200w) for 3s, twice.
6.3免疫印迹分析细胞样品6.3 Western blot analysis of cell samples
具体方法参见1.3.2,一抗为anti-HA(1∶1000)、anti-mGluR5(1∶2000)以及anti-β-actin(1∶500)。For details, see 1.3.2. The primary antibodies were anti-HA (1:1000), anti-mGluR 5 (1:2000) and anti-β-actin (1:500).
7.细胞总RNA的提取及RT-PCR实验:7. Extraction of total cellular RNA and RT-PCR experiment:
7.1转染:7.1 Transfection:
pBK-CMV-HA-CAL/pCDNA3-Flag-mGluR5、-/pCDNA3-Flag-mGluR5分别转染COS-7细胞。COS-7 cells were transfected with pBK-CMV-HA-CAL/pCDNA 3 -Flag-mGluR 5 and -/pCDNA 3 -Flag-mGluR 5 , respectively.
7.2总RNA提取:转染后36小时,分别提取各皿细胞的总RNA。(所有移液器吸头及离心管均用DEPC处理过):7.2 Extraction of total RNA: 36 hours after transfection, extract the total RNA of cells in each dish. (All pipette tips and centrifuge tubes are treated with DEPC):
1)转染相应质粒后的细胞吸弃培养基,DEPC处理过的PBS洗两次,加入Trizol(1mlTrizol/直径35mm的平皿)将样品吹下并转移至1.5ml的离心管中,冰上放置10min。1) After the cells transfected with the corresponding plasmids, suck out the medium, wash twice with DEPC-treated PBS, add Trizol (1ml Trizol/plate with a diameter of 35mm) to blow off the sample and transfer it to a 1.5ml centrifuge tube, and place it on ice 10min.
2)加入200μl氯仿/1ml Trizol裂解液,充分颠倒混匀,冰上放置5min。2) Add 200μl chloroform/1ml Trizol lysate, mix thoroughly by inversion, and place on ice for 5min.
3)4℃12000rpm离心15min。3) Centrifuge at 12000 rpm at 4°C for 15 minutes.
4)小心吸取上层的水相移至新的离心管中,等体积的异丙醇(一般500μl/1ml Trizol裂解液),冰上放置10min。4) Carefully pipette the upper aqueous phase into a new centrifuge tube, add an equal volume of isopropanol (generally 500 μl/1ml Trizol lysate), and place on ice for 10 minutes.
5)4℃12000rpm离心10min。5) Centrifuge at 12000 rpm at 4°C for 10 min.
6)弃上清,加入1ml无RNA酶的75%的乙醇,悬浮沉淀在管底的RNA。6) Discard the supernatant, add 1 ml RNase-free 75% ethanol, and suspend the RNA precipitated at the bottom of the tube.
7)4℃12000rpm离心5min。7) Centrifuge at 12000 rpm at 4°C for 5 minutes.
8)弃去乙醇并尽量完全吸去管壁上的液体,敞开管口室温干燥10min。8) Discard the ethanol and suck up the liquid on the tube wall as much as possible, and open the tube mouth to dry at room temperature for 10 minutes.
9)加入20μl DEPC处理水/1ml Trizol裂解液溶解RNA沉淀。55℃-60℃水浴促进其溶解。9) Add 20μl DEPC-treated water/1ml Trizol lysate to dissolve the RNA precipitate. 55 ℃ -60 ℃ water bath to promote its dissolution.
10)取1μl RNA用紫外分光光度计进行定量,其余放入-80℃冰箱保存。10) Take 1 μl of RNA for quantification with a UV spectrophotometer, and store the rest in a -80°C refrigerator.
11)以1%的琼脂糖凝胶电泳鉴定所提取的总RNA。11) Identify the extracted total RNA by 1% agarose gel electrophoresis.
7.3RNA逆转录为cDNA:7.3 RNA reverse transcription into cDNA:
反转录反应:按下表将各种成分加入PCR管中,总体积为20μl。
混匀,室温放置10min,42℃保温1h,冰上放置2min。获得的cDNA于-20℃保存待用。Mix well, place at room temperature for 10 minutes, keep warm at 42°C for 1 hour, and place on ice for 2 minutes. The obtained cDNA was stored at -20°C until use.
7.4RT-PCR7.4 RT-PCR
1)引物设计:1) Primer design:
mGluR5的羧基末端引物:Carboxy-terminal primer for mGluR 5 :
5′-AAA CCA GAT CTG GAG GAG C-3′5′-AAA CCA GAT CTG GAG GAG C-3′
5′-CGA TGA AGA ACT CTG CGT G-3′5′-CGA TGA AGA ACT CTG CGT G-3′
β-actin引物β-actin primer
5′-CCC ATC TAC GAG GGC TAC GC-3′5′-CCC ATC TAC GAG GGC TAC GC-3′
5′-AGG AAG GAG GGC TGG AAC A-3′5′-AGG AAG GAG GGC TGG AAC A-3′
2)反应体系如下表:
3)PCR最佳反应程序如下:3) The optimal reaction procedure for PCR is as follows:
94℃5分钟→94℃40秒→55℃40秒→72℃40秒→72℃7分钟→30循环。94°C for 5 minutes → 94°C for 40 seconds → 55°C for 40 seconds → 72°C for 40 seconds → 72°C for 7 minutes → 30 cycles.
4)PCR产物的鉴定及分析:4) Identification and analysis of PCR products:
取PCR产物5μl,加入6×上样缓冲液1μl,在2%的琼脂糖凝胶中电泳,紫外灯下观察结果,并用紫外凝胶成像仪扫描并保存结果,以ImageJ软件定量分析。Take 5 μl of PCR product, add 1 μl of 6× loading buffer, electrophoresis in 2% agarose gel, observe the results under ultraviolet light, scan and save the results with an ultraviolet gel imager, and use ImageJ software for quantitative analysis.
7.5统计方法:7.5 Statistical method:
采用SPSS11.5统计软件包对所得数据进行处理。数据以均数±标准差( X±SD)表示,两组数据进行独立样本t检验,P<0.05为差异有统计学意义。The obtained data were processed by SPSS11.5 statistical software package. Data are presented as mean ± standard deviation ( X±SD) indicates that the two groups of data were subjected to independent sample t test, and P<0.05 was considered statistically significant.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710086478 CN101045925A (en) | 2007-03-13 | 2007-03-13 | Mutual action of CAL and mGluR5 and its effect on mGluR5 expression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200710086478 CN101045925A (en) | 2007-03-13 | 2007-03-13 | Mutual action of CAL and mGluR5 and its effect on mGluR5 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101045925A true CN101045925A (en) | 2007-10-03 |
Family
ID=38770847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200710086478 Pending CN101045925A (en) | 2007-03-13 | 2007-03-13 | Mutual action of CAL and mGluR5 and its effect on mGluR5 expression |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101045925A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102043047A (en) * | 2010-11-02 | 2011-05-04 | 中国科学院武汉病毒研究所 | Rapid and economical immunofluorescence method based on Fisher |
-
2007
- 2007-03-13 CN CN 200710086478 patent/CN101045925A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102043047A (en) * | 2010-11-02 | 2011-05-04 | 中国科学院武汉病毒研究所 | Rapid and economical immunofluorescence method based on Fisher |
CN102043047B (en) * | 2010-11-02 | 2013-04-10 | 中国科学院武汉病毒研究所 | Rapid and economical immunofluorescence method based on Fisher |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1310942C (en) | Suppressor gene | |
CN1871239A (en) | Modulation of beta-catenin/tcf-activated transcription | |
CN1768076A (en) | Amyloid-beta(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use therof. | |
CN1556863A (en) | Methods and compositions related to HPV-associated precancerous and cancerous growths, including CIN | |
CN1520311A (en) | Cancer vaccine contg. cancer antigen based on tumor suppressor gene WT1 product and cationic liposomes | |
CN1630663A (en) | Synthetic or natural peptides that bind protein phosphatase 2A, methods for their identification and uses | |
CN1668641A (en) | Truncated tau protein | |
CN1529753A (en) | disease-associated protein | |
CN1816564A (en) | Rasgap derived peptide for selectively killing cancer cells | |
CN1852919A (en) | Agonist polypeptide of receptor for ZOT and zonulin | |
CN1720442A (en) | CIZI replication protein | |
CN101045925A (en) | Mutual action of CAL and mGluR5 and its effect on mGluR5 expression | |
CN1745094A (en) | Peptides, their antibodies, and their use in the treatment of central nervous system injuries | |
CN101065398A (en) | Peptides and APL-type derivatives of hsp60 and pharmaceutical compositions | |
CN1795205A (en) | Spex compositions and methods of use | |
CN1568374A (en) | Method for identifying compounds modulating reverse cholesterol transport | |
CN1478149A (en) | Method of screening physiologically active substance | |
CN1274827C (en) | Cancer gene and its coded protein and special cell line | |
CN1190491C (en) | PRV-1 gene and the use thereof | |
CN1781944A (en) | Sperm protein monoclonal antibody and its preparing method and use | |
CN1227263C (en) | Peptides for diagnosis and treatment of autoimmune diseases | |
CN1239700C (en) | Human liver cancer related gene, encoded product and use thereof | |
CN1740194A (en) | A kind of tumor correlated albumen and encoding gene thereof and application | |
CN1209369C (en) | Cell death inducing protein and its coding sequence and use | |
CN101058808A (en) | Breast cancer relevant p69 gene, coding protein and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20071003 |